# Multiple Myeloma Manager vs ASCO Guidelines

The clearest difference is rating: ASCO Guidelines at 4.8 against Multiple Myeloma Manager's 4.0. ASCO Guidelines also leads on ratings volume (259 vs 1) and iOS requirement (10.0 vs 14.0). On price, update cadence, ads and in-app purchases there is nothing between them.

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ASCO Guidelines holds the better App Store score, 4.8 against 4.0. That said, the two scores are not equally well evidenced: ASCO Guidelines has 259 ratings behind it against 1, so its average is the more settled of the two.

Both ship on a similar rhythm, roughly every 5 months. The most recent releases landed on October 6, 2026 and October 24, 2026 respectively.

## The numbers

| Metric | Multiple Myeloma Manager | ASCO Guidelines |
| --- | --- | --- |
| Price | Free | Free |
| Rating | [4.0 (1 ratings)](https://appshunter.io/ios/app/multiple-myeloma-manager/id869026450/reviews) | **[4.8 (259 ratings)](https://appshunter.io/ios/app/asco-guidelines/id1238827183/reviews)** |
| Number of ratings | 1 | **259** |
| Positive reviews | — | 57.1% of reviews |
| In-app purchases | No | No |
| Ads | No | No |
| Update frequency | Every 5 months | Every 5 months |
| Monetization | Free | Free |
| Size | 20 MB | 411 MB |
| Requires iOS | 14.0 | **10.0** |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Age rating | 12+ | 12+ |
| Developer | [@Point of Care](https://appshunter.io/developer/916313675) | [American Society of Clinical Oncology](https://appshunter.io/developer/1513043539) |

## What reviewers say

### Multiple Myeloma Manager

[App page](https://appshunter.io/ios/app/multiple-myeloma-manager/id869026450)

This app helps individuals manage their daily symptoms, medications, and treatments related to Multiple Myeloma. It provides visual trend analysis through charts and allows users to share data with healthcare providers for better monitoring and understanding of their condition.

**Highlights:** Daily symptom and progress tracking, Medication and treatment management with reminders, Photo upload for visible symptom sharing, Care provider connection for progress monitoring, Educational resources on Multiple Myeloma, Data visualization with charts and graphs, Reward system with animated badges

**Features:** macOS Compatibility

**In-app purchases:** none


### ASCO Guidelines

[App page](https://appshunter.io/ios/app/asco-guidelines/id1238827183)

Access comprehensive cancer care guidelines and interactive tools to inform treatment decisions. This app supports healthcare providers, patients, and caregivers in implementing recommended cancer care options for various cancer types, aiming to improve the quality of care.

**Highlights:** Guideline recommendations for cancer care, Interactive treatment decision tools, Supports healthcare providers, Informs patients and caregivers, Covers various cancer types, Regularly updated content

**Features:** macOS Compatibility, Vision Pro support

**In-app purchases:** none


## Frequently asked questions

### Is Multiple Myeloma Manager free?

Multiple Myeloma Manager is free to download, with no in-app purchases.

### Is ASCO Guidelines free?

ASCO Guidelines is free to download, with no in-app purchases.

### Which has better reviews, Multiple Myeloma Manager or ASCO Guidelines?

ASCO Guidelines is rated higher. Multiple Myeloma Manager averages 4.0 out of 5 from 1 ratings, while ASCO Guidelines averages 4.8 from 259 ratings.

### Do Multiple Myeloma Manager or ASCO Guidelines have ads?

Neither Multiple Myeloma Manager nor ASCO Guidelines shows ads.

### Which is updated more often, Multiple Myeloma Manager or ASCO Guidelines?

Multiple Myeloma Manager ships an update every 5 months, and ASCO Guidelines every 5 months. Most recently, Multiple Myeloma Manager was updated on October 6, 2026 and ASCO Guidelines on October 24, 2026.

---

*Compared by [AppsHunter](https://appshunter.io/) from daily US App Store data. Review summaries are generated from verbatim App Store reviews.*